Tag Archives: Catabasis Pharmaceuticals

Analysts Offer Insights on Healthcare Companies: and Catabasis Pharmaceuticals (NASDAQ: CATB)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Catabasis Pharmaceuticals (CATB – Research Report) with bullish sentiments. Catabasis Pharmaceuticals (CATB) In a report issued on May 13, Hartaj Singh

Wedbush Keeps a Buy Rating on Catabasis Pharmaceuticals (CATB)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Catabasis Pharmaceuticals (CATB – Research Report), with a price target of $15.00. The company’s shares closed last Thursday at $6.71. According to TipRanks.com, Moussatos is a

Oppenheimer Sticks to Their Buy Rating for Catabasis Pharmaceuticals (CATB)

In a report released today, Hartaj Singh from Oppenheimer reiterated a Buy rating on Catabasis Pharmaceuticals (CATB – Research Report), with a price target of $60.00. The company’s shares closed last Monday at $4.66, close to its 52-week low of

Catabasis Pharmaceuticals (CATB) Receives a Buy from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Catabasis Pharmaceuticals (CATB – Research Report) today and set a price target of $18.00. The company’s shares closed last Monday at $5.94. According to TipRanks.com, Moussatos is a 2-star analyst with

Wedbush Sticks to Their Buy Rating for Catabasis Pharmaceuticals (CATB)

In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on Catabasis Pharmaceuticals (CATB – Research Report), with a price target of $18.00. The company’s shares closed last Monday at $5.61. According to TipRanks.com, Moussatos ‘ ranking

Wedbush Reaffirms Their Buy Rating on Catabasis Pharmaceuticals (CATB)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Catabasis Pharmaceuticals (CATB – Research Report), with a price target of $18. The company’s shares opened today at $8.26. According to TipRanks.com, Moussatos is ranked 0